MSH2 and prostate cancer: In contrast, the IMPACT study, a prospective international trial that followed 644 men with LS and 318 age-matched non-carriers, found that prostate cancer incidence was significantly higher in MSH2 (4.3%) and MSH6 (3.0%) carriers, with no cases observed in MLH1 carriers [153].